The efficacy of radioimmunotherapy (RIT) for patients with relapsed non-Hodgkin's lymphoma (NHL) is limited by non-specific delivery of radiation to normal tissues due to the long circulating half-life of radiolabeled anti-CD20 antibodies (Ab). Pretargeted RIT using a covalent conjugate of the 1F5 anti-CD20 Ab with streptavidin (SA) has been shown to augment the efficacy of RIT and decrease toxicity compared with a directly labeled 1F5 Ab. We have engineered a tetravalent single-chain 1F5 (scFv) 4 SA fusion protein and compared it to the 1F5-SA conjugate. Athymic mice bearing Ramos lymphoma xenografts received either the conjugate or fusion protein, followed 20 hours later by a biotin-N-acetyl-galactosamine clearing agent, followed 4 hours later by 111 In-DOTA-biotin. After 24 hours, 11.4 ± 2.1% of the injected dose of radionuclide was present per gram of tumor (% ID/g) using 1F5 (scFv) 4 SA compared with 10.8 ± 2.5% ID/g with 1F5 Ab-SA. Superior tumor-to-normal organ ratios of radioactivity were consistently seen using the fusion protein compared to the chemical conjugate (e.g., tumor-toblood ratio >65:1 after 48 hours with the fusion protein, but <7:1 with the conjugate). More than 90% of lymphoma-bearing mice could be cured with minimal toxicity using either reagent followed by 1200 µCi of 90
INTRODUCTION
Radioimmunotherapy (RIT) using anti-CD20 antibodies (Ab) conjugated to 131 I or 90 Y has shown promising efficacy and tolerable toxicity in many patients with indolent Non Hodgkin's lymphoma (NHL). [1] [2] [3] [4] [5] Recent data has suggested that improved efficacy can be achieved using standard non-myeloablative doses of RIT with chemotherapy during early patient treatment encounters. [6] [7] [8] In particular, outstanding results have been seen using conventional RIT as a single-agent as frontline therapy for newly diagnosed patients. 9 However, despite remission rates of 60-80% and complete response rates of 25-40% in multiply-treated NHL patients, most of these relapsed/refractory patients who receive non-myeloablative doses of RIT subsequently relapse and the median progression free survival is only ~1 year. 10 The failure of conventional one-step RIT to completely eradicate lymphoma in these cases is presumably due to inadequate delivery of sufficient radiation since tumor-to-normal organ ratios of absorbed radioactivity are relatively low. 11, 12 One major obstacle limiting the efficacy of RIT is the protracted circulating half-life of conventional radiolabeled Abs, which necessitates non-specific exposure of normal organs, particularly the bone marrow, to radioactivity. Pretargeted RIT (PRIT) is a strategy that may address this limitation and improve the therapeutic index by separating the localization of Ab to tumor sites from the delivery of the therapeutic radionuclide. One PRIT approach utilizes the high affinity streptavidin (SA)-biotin system in which an Ab-SA conjugate and radioactive biotin are administered separately. [13] [14] [15] [16] The localization of the Ab-SA component to tumor is relatively slow and an unbound portion of the conjugate remains in circulation. However, because no radionuclide is attached, there are no toxic consequences. After maximal accumulation of Ab-SA conjugate in targeted tissues, a clearing agent (CA) is administered to remove circulating Ab-SA conjugate. 17, 18 Therapeutic radiobiotin is then administered and penetrates tumors rapidly because of its small size and binds with high affinity to the pretargeted Ab-SA conjugate. Excess radiobiotin is rapidly excreted by the kidney. This PRIT approach has been shown to improve the For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From ratios of radiation delivered to tumors compared to normal organs in both preclinical and clinical models.
17, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Most pretargeting studies have employed chemically heterogeneous Ab-SA conjugates produced using heterobifunctional cross-linkers (e.g., some Ab-SA conjugates have consisted of 80-85% 1:1 Ab:SA conjugates, 5-10% 1:2 Ab:SA conjugates, and 6-10% molecules of higher molecular weight). In contrast, genetically engineered Ab-SA fusion proteins (FP) are more homogeneous, more amenable to scale-up and approval by regulatory agencies, and more economical to produce. It has recently been demonstrated that a recombinant FP composed of an anti-CD20 single-chain Ab (scFv) and SA could be expressed at high levels in the periplasmic space of E. coli. 25 Additional fusion constructs targeting the CD25, EpCAM, and TAG72 antigens have also been expressed, purified in high yield, and investigated. 18, 24, 29 These Ab-SA FPs spontaneously form tetramers, preserve the full antigen and biotin binding capabilities of both parent molecules, and bind more avidly to tumor cells than bivalent Ab-SA chemical conjugates.
In view of these compelling advantages, we engineered an anti-CD20 FP combining the single-chain Fv segment of the 1F5 murine anti-human CD20 Ab with SA to compare its biodistribution, pharmacokinetics, tumor localization index, and therapeutic efficacy with a corresponding anti-CD20 Ab-SA synthetic conjugate. We report here that the tetravalent FP localizes to tumors better than the chemical conjugate and is at least equivalent therapeutically.
MATERIALS AND METHODS

Cell lines
The CD20-expressing Ramos cell line (Burkitt's Lymphoma) and a hybridoma expressing a nonspecific IgG 2 a negative control Ab, HB-8181, were obtained from American Type Culture Collection (Bethesda, MD). The 1F5 hybridoma cell line expressing the murine IgG 2 a anti-human CD20 Ab was a gift from Clay Siegall (Seattle Genetics, Seattle, WA). Cell
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From lines were maintained using medium previously described. 20 Cell viability exceeded 95% by trypan blue exclusion.
Antibodies
The 1F5 and HB8181 Abs were produced from the respective hybridomas using a hollow fiber bioreactor system in the monoclonal Ab production facility at the Fred Hutchinson Cancer
Research Center (FHCRC; Seattle, WA).
Construction of a 1F5 (scFv) 4 SA fusion protein expressing plasmid
The 1F5 heavy-chain (V H ) and light-chain (V L ) genes were cloned from the 1F5 hybridoma as published. 30 The 1F5 scFvSA gene for the current study was engineered by fusing the scFv gene to the full-length genomic SA of Streptomyces avidinii as described. 25, 29 The resultant plasmid (A15-1-2) encoding the 1F5 scFvSA gene contained a 25-mer Gly 4 Ser linker 25 between the V H and V L fragments. The SA gene was then joined to the scFv region using a GSGSA peptide linker. The FP was expressed from an IPTG-inducible lac promoter.
Expression and purification of 1F5 (scFv) 4 SA fusion protein
An E. coli XL1 Blue (Stratagene, La Jolla, CA) transformant of the 1F5 scFvSA construct (A15-1-2) was grown in shaker flasks for qualitative expression of the FP and subsequently in a 4 L fermentor (BioFlo 3000, New Brunswick Scientific, Edison, NJ) using methods similar to those described. 25 Cultures were induced with 0.1 mM IPTG and cells harvested after 44 hours (hr). The cell paste was washed three times with PBS and the lysate purified by iminobiotin column chromatography. 25 The eluted FP was treated with 20% DMSO for 2 hr to reduce aggregates, extensively dialyzed in PBS, filter-sterilized, formulated in 5% sorbitol, and stored at -80 o C.
In vitro characterization of 1F5 (scFv) 4 SA fusion protein
The FP was analyzed by SDS-PAGE on 4-12% Tris-glycine gels (Invitrogen) under nonreducing conditions. For immunoblot analysis, a goat anti-SA Ab (Vector Laboratories,
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From Burlingame, CA) was used to detect the FP on a PVDF membrane (Invitrogen) using a peroxidase-conjugated F(ab') 2 fragment of rabbit anti-goat IgG (Jackson ImmunoReaserch, West Grove, PA) and a TMB substrate (Vector Laboratories). Size exclusion HPLC analysis was performed on a Zorbax GF-250 column (4.6 X 250 mm, Agilent, Palo Alto, CA) with a 20 mM sodium phosphate/0.5 M sodium chloride/15% DMSO/pH 6.8-7.0 mobile phase. Unpurified protein samples were quantified using a rhodamine-biotin assay as described. 25 The concentration of the FP in the crude lysate was calculated using the molecular weight of the 1F5 Y (PerkinElmer) radiolabeling of DOTA-biotin for PRIT or intact DOTA-1F5 Ab for conventional RIT was performed as described. 20 Radiochemical purity was typically greater than 99% as determined by HPLC, and labeling efficiencies were >93%.
DOTA-biotin was synthesized as described. 
Pharmacokinetic and biodistribution studies
To assess whole blood clearance, 1. Two separate toxicity experiments assessing leukocyte, hemoglobin, and platelet counts, plus aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, and blood urea nitrogen (BUN) levels, were performed using mice treated as described above using methods previously defined. 20 Surviving mice were maintained for 12 months and serum again analyzed for AST, ALT, BUN, and creatinine to assess potential long-term kidney and liver toxicities. coli with a molecular weight of 174,368 Da. One (scFv) 4 SA transformant (A15-1-2) was grown in a 4 L fermentor and expressed 100 mg/L of FP. The product was purified from homogenized cell extracts with a 59% yield on a single iminobiotin affinity column and a ~50% overall purification yield. SDS-PAGE analysis demonstrated 95% homogeneity of the FP after iminobiotin chromatography (Fig. 1) 
RESULTS
Expression
Blood clearance of 1F5 (scFv) 4 SA fusion protein
Blood clearance studies were conducted in female BALB/c athymic mice to assess the pharmacokinetic differences between 1F5 (scFv) 4 SA and 1F5 Ab-SA (Fig. 2a) (Fig. 3) . Similar biodistributions of 111 In-DOTA-biotin were obtained in tumors and blood following PRIT (Fig. 3a) employing 1F5 (scFv) 4 SA, B9E9
(scFv) 4 SA, and 1F5 Ab-SA. After 24 hrs, peak 111 In-DOTA-biotin levels were 11.4 ± 2.1% ID/g with 1F5 (scFv) 4 SA, 10.8 ± 2.5% ID/g with 1F5 Ab-SA, and 11.2 ± 1.5% ID/g with B9E9
(scFv) 4 SA. The biodistributions of radioactivity in normal organs were similar with each pretargeted anti-CD20 construct and with the non-specific CC49 (scFv) 4 SA negative control, ranging from <1% ID/g in colon to <2.5 % ID/g in kidney (data not shown). However, circulating blood levels of 111 In-DOTA-biotin after 24 hrs were notably higher in mice receiving 1F5 Ab-SA (1.6 ± 0.2% ID/g), compared to either B9E9 (scFv) 4 SA (0.2 ± 0.1% ID/g) or 1F5
(scFv) 4 SA (0.3 ± 0.1% ID/g). At all timepoints, control animals injected with the non-binding CC49 (scFv) 4 SA had negligible tumor uptake of radioactivity (0.9 ± 0.1% ID/g) demonstrating the specificity of targeting.
All three anti-CD20 pretargeting constructs had superior biodistributions compared to conventional RIT employing directly radiolabeled 111 In-DOTA-1F5 whole Ab (Fig. 3b) . In contrast to the PRIT biodistribution experiments, only 7.8 ± 1.4% ID/g was present in tumor after 24 hrs using 111 In-DOTA-1F5 Ab, decreasing to 5.9 ± 2.0% ID/g after 48 hrs, and 4.1 ± 1.2%
ID/g of tumor after 72 hrs. The amount of radioactivity remained high in the blood for prolonged periods following administration of the 111 In-DOTA-1F5 Ab, with 15.7 ± 1.6% ID/g, 12.3 ± 2.1% ID/g, and 8.7 ± 2.0% ID/g in blood after 24, 48, and 72 hrs, respectively. PRIT using either 1F5
(scFv) 4 SA, B9E9 (scFv) 4 SA, or the 1F5 Ab-SA yielded favorable tumor-to-normal organ ratios at all timepoints, however, ratios were most favorable using the pretargeted FPs due their more rapid clearance from blood and superior tumor retention. Using the pretargeting approach with
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From 1F5 (scFv) 4 SA, the tumor-to-normal organ ratios after 24 hrs varied from a high of ~50:1 in blood to the lowest being 26:1 in kidney (Fig. 4) . In contrast, the tumor-to-blood ratio was only 9:1 after 24 hrs using pretargeted 1F5 Ab-SA and the tumor-to-kidney ratio was 19: 
Pretargeted radioimmunotherapy with anti-CD20 fusion proteins and conjugates
The therapeutic efficacies of the various PRIT reagents were compared in athymic mice (Fig. 5a) , with required euthanasia by day 20 (Fig. 6) . The 1F5 Ab-SA group receiving 200 μCi 90 Y-DOTA-biotin showed a transient initial delay in tumor growth (Fig. 5a ), but all mice required euthanasia 27-30 days after treatment ( Fig. 5c and d, respectively) . All mice receiving either B9E9
(scFv) 4 SA or 1F5 Ab-SA achieved CRs with 1200 μCi 90 Y-DOTA-biotin by day 12 (Fig. 5e ). All
CRs were durable for the full time course of the study (greater than 150 days), suggesting that these mice were cured (Fig. 6 ). (Fig. 7b) . When the dose of 1F5 (scFv) 4 SA was increased to 2.8 nmol to compensate for its shorter half-life, the number of CRs increased to 7 of 10 treated with 800 μCi of 90 Y-DOTA-biotin and 9 of 10 receiving 1200 μCi of 90 Y-DOTAbiotin (Fig. 7b ). CRs were seen by day 10 in all 10 mice treated with 1.4 nmol 1F5 Ab-SA followed by either 800 or 1200 μCi of radiobiotin. All mice achieving CR remained tumor-free for the entire observation period (>150 days, Fig. 8 ). DOTA-1F5 Ab. Higher doses of directly labeled 90 Y-DOTA-1F5 were not studied since they were lethal in 100% of mice. 17 Weekly leukocyte, platelet, and hemoglobin values were obtained using blood sampled from the retro-orbital venous plexus (Table 1) . Leukocyte counts in all groups reached a nadir 7 to 14 days following radiobiotin. Mice treated with 1200 μCi of 90 Y-DOTA-biotin after the CC49 (scFv) 4 SA produced a leukocyte nadir (51% ± 39% of initial leukocyte count) similar to 1F5 Ab-SA (39% ± 54%), 1F5 (scFv) 4 SA (48% ± 36%), and B9E9
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(scFv) 4 SA (41% ± 27%). In contrast, hemoglobin values and platelet levels did not decrease in any pretargeted group. Mice injected with 200 μCi of conventional 90 Y-DOTA-1F5 Ab exhibited more profound decrements in the leukocyte count (76% ± 40% by day 7) as well as anemia (48% ± 17% drop in hemoglobin by day 14) and thrombocytopenia (43% ± 9% decrement in platelet count by day 7). All mice in the conventional RIT group died of toxicity by day 30.
In a separate study using the same treatment protocol, blood was sampled weekly for AST, ALT, creatinine, and BUN levels. There were no significant differences in BUN, creatinine, or transaminase levels detected between groups of mice treated with either directly- 
DISCUSSION
The recent development of radiolabeled Abs presents a unique opportunity to treat hematologic malignancies by delivering high doses of radiation specifically to tumor sites while sparing normal organs. Radiolabeled Abs using either 131 I or 90 Y have been used by many groups at non-myeloablative doses to target a variety of NHL cell surface antigens other than CD20 including CD19, CD22, CD37, and HLA class II molecules. [34] [35] [36] The most promising trials have documented the safety and efficacy of 131 I-tositumomab (Bexxar®) and 90 Y-ibritumomab (Zevalin®) targeting CD20 for relapsed NHL patients. [1] [2] [3] [4] [5] However, despite remission rates of 60-80% and CR rates of 25-40% with these anti-CD20 radioimmunoconjugates, most patients relapse with a median progression free survival of only 6-12 months. 10 One major obstacle limiting the efficacy of RIT is the relatively protracted circulating half-life of conventional radiolabeled Abs that results in non-specific exposure of normal organs to radioactivity. In this 4 -SA, or 1F5 Ab-SA chemical conjugate. Data represent mean (n = 10) ± SD. *P values are representative of significant differences between the 1F5 (scFv) 4 -SA fusion protein and directly labeled DOTA-1F5 Ab.
report, we have attempted to overcome this limitation and improve the target-to-non-target ratios of absorbed radiation doses using a PRIT method that permits rapid clearance of the targeting Ab construct from the blood. Several studies in solid tumor and hematologic malignancies have supported the superiority of PRIT compared to conventional RIT because of the more rapid uptake of radiolabel in the tumor, more rapid blood clearance of radioactivity, and improvement in tumor-to-blood and tumor-to-normal organ radioactivity ratios.
17-24,27,37-40 Several pretargeting methods have been developed including: 1) bispecific Abs that target a specific target site and possess a hapten-binding site 41 , 2) biotinylated Abs that bind to SA 42 and, 3) Abs conjugated to SA or avidin that bind to biotin. 21, 43 While the optimal PRIT strategy remains to be elucidated,
we have chosen to pursue the 2-step Ab-SA approach.
Although PRIT offers striking advantages, some caveats to the clinical implementation of this strategy should also be acknowledged. PRIT requires multiple injections of reagents at defined time intervals and necessitates the validation of the safety of each step. The immunogenicity of SA may limit the ability to administer multiple cycles of therapy. Moreover, endogenous biotin and serum biotinidases may limit the therapeutic success of radiolabeled biotin binding to SA, although the presence of endogenous biotin and serum biotinidases have not been serious impediments to the success of this approach. 28, 44 Most Ab-SA pretargeting studies have utilized chemically synthesized covalent conjugates that deliver at least 5-fold higher doses of absorbed radiation to tumor sites compared to conventional RIT, while at the same time exposing normal tissues to lower doses of irradiation.
Chemically cross-linked conjugates between whole Abs and SA, however, are invariably mixtures of heterogeneous protein species that lack uniformity and potentially impact the biotin- 45 Recombinant FPs also have the advantage of spontaneous tetramer formation, allowing amplification of the amount of radiation delivered to tumor cells. Moreover, genetically engineered FPs can be expressed at high levels in the periplasmic space of E. coli, and are thus easier and less costly to manufacture and purify than covalent Ab-SA conjugates.
Based on the advantageous properties of FPs, we have produced and characterized an anti-CD20 1F5 (scFv) 4 SA FP for PRIT of NHL. This FP maintains the full antigen and biotin binding capabilities of the parent 1F5 Ab and SA, and can be rapidly and quantitatively directed from the blood to the liver for hepatic processing by a biotinylated N-acetyl-galatosaminecontaining CA. This attribute, coupled with the more rapid inherent clearance of the FP compared to chemical conjugates, results in extremely low serum concentrations of SA after CA administration. Our studies showed that both chemically conjugated 1F5 Ab-SA and anti-CD20 molecular FPs were markedly superior to the conventional radiolabeled Ab in directing radiotherapy to tumor cells. Biodistribution experiments demonstrated that the anti-CD20 1F5 (scFv) 4 SA molecular FP was superior to the chemically synthesized 1F5 Ab-SA covalent conjugate in this regard, as shown by improved tumor-to-normal organ ratios of absorbed radiation using the FP (Fig. 4) . The more efficient clearance of the FP construct from the bloodstream resulted in tumor-to-blood ratios, and thus tumor-to-normal organ ratios, of absorbed radioactivity that were at least 3-5 fold greater when the FP was employed compared to ratios obtained with the use of the pretargeted chemical conjugate.
Although the demonstration of substantial improvements in tumor-to-normal ratios of absorbed radiation using the 1F5 (scFv) 4 SA FP compared to the covalent conjugate were encouraging, it was important to perform therapy experiments comparing efficacies and toxicities using PRIT. These therapy experiments showed that optimal doses of the FP produced response Although one prior report presents murine biodistribution data using an anti-CD20
(scFv) 4 SA, 25 we believe this report is the first to compare such a FP head-to-head with the corresponding Ab-SA chemical conjugate and with the corresponding directly labeled Ab.
Furthermore, our study is the first to report controlled animal therapy experiments and toxicity data. Based on our findings, we conclude that anti-CD20 (scFv) 4 For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
